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a b s t r a c t
Human parainﬂuenza virus type 1 (hPIV1) and type 3 (hPIV3) initiate infection by sialic acid binding.
Here, we investigated sialic acid linkage speciﬁcities for binding and infection of hPIV1 and hPIV3 by
using sialic acid linkage-modiﬁed cells treated with sialidases or sialyltransferases. The hPIV1 is bound to
only α2,3-linked sialic acid residues, whereas hPIV3 is bound to α2,6-linked sialic acid residues in
addition to α2,3-linked sialic acid residues in human red blood cells. α2,3 linkage-speciﬁc sialidase
treatment of LLC-MK2 cells and A549 cells decreased the infectivity of hPIV1 but not that of hPIV3.
Treatment of A549 cells with α2,3 linkage-speciﬁc sialyltransferase increased infectivities of both hPIV1
and hPIV3, whereas α2,6 linkage-speciﬁc sialyltransferase treatment increased only hPIV3 infectivity.
Clinical isolates also showed similar sialic acid linkage speciﬁcities. We concluded that hPIV1 utilizes
only α2,3 sialic acid linkages and that hPIV3 makes use of α2,6 sialic acid linkages in addition to α2,3
sialic acid linkages as viral receptors.
& 2014 Published by Elsevier Inc.
Introduction
Human parainﬂuenza virus type 1 (hPIV1) is a respiratory
pathogen that most frequently causes laryngotracheobronchitis
in children, and human parainﬂuenza virus type 3 (hPIV3), which
is generally more virulent than hPIV1, is the second most fre-
quently isolated virus from patients with pneumonia and bronch-
iolitis, mainly in infants younger than 5 years old (Chanock, 2001;
Sinaniotis, 2004). These human parainﬂuenza viruses (hPIVs),
which belong to the genus Respirovirus and the family Paramyx-
oviridae, have two spike glycoproteins, hemagglutinin-neura-
minidase (HN) glycoprotein and fusion glycoprotein, on the viral
surfaces. hPIVs bind to terminal sialic acids of glycoconjugates on
the host cell surface through HN glycoprotein (Scheid et al., 1972;
Tozawa et al., 1973).
Sialic acids are typically found at the terminals of oligosacchar-
ides on gangliosides and glycoproteins, and they are mainly
linked to the galactose residue by α2,3- or α2,6-linkage or are
polymerized by α2,8- or α2,9-linkage (Kirsch et al., 2009; Suzuki,
2005). Inﬂuenza A viruses isolated from several animal species
recognized different terminal sialic acid linkages. Avian inﬂuenza
A viruses preferentially bind to α2,3-linked sialic acid residues. In
contrast, human inﬂuenza A viruses show predominant binding
speciﬁcity to α2,6-linked sialic acid residues (Matrosovich et al.,
1997). Such a virus binding speciﬁcity for sialic acid linkages is
believed to be one of the major determinants of viral host range
and tissue tropism.
We previously reported that hPIV1 and hPIV3 show different
binding speciﬁcities for the terminal sialic acid linkages of
some gangliosides: hPIV1 preferentially binds to α2,3-linked
sialic acids, whereas hPIV3 strongly binds both to α2,3- and
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α2,6-linked sialic acid residues at the terminals of oligosacchar-
ides containing branched N-acetyllactosaminoglycans (Suzuki
et al., 2001b). In the present study, we compared cell infectiv-
ities of hPIV1 and hPIV3 with their binding speciﬁcities for
overall sialic acid linkages on cell surfaces containing ganglio-
sides and glycoproteins. We evaluated the binding activities and
infectivities of hPIV1 and hPIV3 for sialic acid linkage-modiﬁed
cells by treatment with sialidase or/and sialyltransferase. We
found that hPIV1 uses terminal α2,3-linked sialic acids only and
that hPIV3 uses terminal α2,6-linked sialic acid residues in
addition to α2,3-sialic acid linkages as the viral cell receptor.
Results
Hemagglutination of sialic acid linkage-modiﬁed hRBC by hPIV1 and
hPIV3
To investigate the difference in virus binding to the sialic acid
linkages on the cell surface, we modiﬁed the terminal sialic acid
linkages on the surface of human red blood cells (hRBC), on which
various sialic acid linkages for hRBC including α2,3 and α2,6
linkages existed (Aminoff et al., 1980; Bratosin et al., 1995; Bulai
et al., 2003), by treatment with sialidases. hRBC were treated with
sialidase from Arthrobacter ureafaciens (AUSD) to remove all
terminal sialic acids or with cloned α2,3 neuraminidase from
Salmonella typhimurium LT2 (23SD) to remove preferentially
α2,3-linked sialic acid residues (Hoyer et al., 1991; Rogerieux et
al., 1993). These sialidases hydrolyze both the terminal sialic acids
at gangliosides and glycoproteins (Hoyer et al., 1991; Uchida et al.,
1979). hPIV1 and hPIV3 binding speciﬁcities for α2,3 and α2,6
sialic acid linkages were evaluated by hemagglutination of these
sialidases-treated hRBC (AUSD-hRBC and 23SD-hRBC). AUSD treat-
ment resulted in the loss of both hemagglutination activities of
hPIV1 and hPIV3, indicating that hPIV1 and hPIV3 bind to hRBC via
terminal sialic acids only (Table 1). 23SD treatment resulted in the
loss of hemagglutination activity of hPIV1, whereas hemagglutina-
tion activity of hPIV3 remained, although the activity of hPIV3 was
decreased (Table 1). hPIV3 probably recognized α2,6-linked sialic
acids which remained on the surface of hRBC after 23SD
treatment.
To conﬁrm that the remaining binding of hPIV3 after 23SD
treatment is not due to the recognition of α2,3-linked sialic acid
residues, we evaluated viral hemagglutination activity using α2,3-
or α2,6-linked resialylated hRBC. AUSD-treated hRBC were incu-
bated with a reaction solution containing cytidine-5'-monopho-
spho-N-acetylneuraminic acid sodium salt (CMP-Sia) as a sialic
acid donor and α2,3-sialyltransferase from Photobacterium phos-
phoreum (ST3) or α2,6-sialyltransferase from Photobacterium dam-
selae (ST6), which transfers α2,3- or α2,6-linked sialic acids to the
terminal galactosides, respectively, with a wide substrate range
(Tsukamoto et al., 2007; Yamamoto et al., 1998, 1996).
Resialylation hardly induced lysis of AUSD-treated hRBC. We
measured viral hemagglutination activity by using these resialy-
lated hRBC (ST3-hRBC and ST6-hRBC). ST3 treatment resulted in
recovery of both hemagglutination activities of hPIV1 and hPIV3;
however, ST6 treatment resulted in the recovery of the activity of
hPIV3 but not that of hPIV1 (Table 1). We also measured viral
hemagglutination activity by using resialylated hRBC treated with
mammalian sialyltransferase, rat α2,3-(N)-sialyltransferase
ST3Gal-III (ST3N) or α2,6-(N)-sialyltransferase ST6Gal-I (ST6N),
which transfers α2,3- or α2,6-linked sialic acids to the terminal
galactosides of N-glycoproteins, respectively (Kaludov et al., 2001;
Lee et al., 1994; Sánchez-Felipe et al., 2012; Williams et al., 1995).
Viral hemagglutination with ST3N-treated hRBC (ST3N-hRBC) or
ST6N-treated hRBC (ST6N-hRBC) was similar to that with ST3- or
ST6-treated hRBC (Table 1). We concluded that hPIV1 recognized
α2,3-linked sialic acid residues only and that hPIV3 recognized
α2,6-linked sialic acid residues in addition to α2,3-linked sialic
acid residues on the surface of hRBC.
Hemadsorption activities of cell-expressed HN1 and HN3
glycoproteins with sialidase- or sialyltransferase-treated hRBC
We checked the binding activities of HN glycoprotein from
hPIV1 (HN1 glycoprotein) and HN glycoprotein from hPIV3 (HN3
glycoprotein) to α2,3-linked or α2,6-linked sialic acids by hemad-
sorption assays using sialidase- or sialyltransferase-treated hRBC.
Monolayers of HN1 or HN3 glycoprotein-expressing African green
monkey kidney (COS-7) cells were incubated with sialidase-
treated hRBC (AUSD-hRBC and 23SD-hRBC) or sialyltransferase-
treated hRBC (ST3-hRBC, ST3N-hRBC, ST6-hRBC and ST6N-hRBC).
Bound hRBC were quantiﬁed by the amount of hemoglobin. HN1
glycoprotein-expressing cells absorbed to ST3-hRBC, whereas HN3
glycoprotein-expressing cells absorbed to 23SD-hRBC, ST3-hRBC
and ST6-hRBC (Fig. 1A and B). Neither HN1 nor HN3 glycoprotein-
expressing cells absorbed to AUSD-hRBC (Fig. 1A). The results for
mammalian sialyltransferase-treated hRBC (ST3N-hRBC and ST6N-
hRBC) were similar to those for ST3- and ST6-treated hRBC
(Fig. 1C). Fusion glycoproteins did not show any hemadsorption
activity (data not shown) (Chu et al., 2013). Each HN glycoprotein
showed the same sialic acid linkage speciﬁcity as the correspond-
ing virus particle, indicating that the hPIV binding speciﬁcities for
sialic acid linkages were dependent on the HN glycoproteins only.
Infectivities of hPIV1 and hPIV3 to sialidase-treated cells
To determine whether binding speciﬁcities of hPIV1 and hPIV3
for sialic acid linkages affect infectivities of host cells, we inves-
tigated the infectivities of hPIV1 and hPIV3 to sialidase-treated
cells. Conﬂuent monolayers of Lewis lung carcinoma-monkey
kidney (LLC-MK2) cells were treated with serially diluted 23SD
for α2,3 linkage-speciﬁc desialylation or AUSD for all linkage
desialylation. Infectivities of hPIV1 and hPIV3 were measured in
these sialidase-treated cells. 23SD treatment decreased the infec-
tivity of hPIV1 in 23SD-dependent manner. In contrast, infectivity
of hPIV3 was hardly affected by 23SD treatment (Fig. 2A). Both
hPIV1 and hPIV3 scarcely infected the AUSD-treated monolayer
(Fig. 2A). We also measured amounts of α2,3- and α2,6-linked
sialic acid residues on the surfaces of sialidase-treated cells by
ﬂowcytometric analysis using Maackia amurensis agglutinin (MAA)
or Sambucus nigra agglutinin (SNA), which recognize α2,3-linked
or α2,6-linked sialic acid residues, respectively. We conﬁrmed
that 23SD treatment speciﬁcally removed α2,3-linked sialic acids
and that AUSD treatment removed both α2,3-linked and α2,6-
linked sialic acids (Fig. 2B). We also measured viral infectivities in
23SD-treated human lung adenocarcinoma epithelial cells (A549
cells) cells. Similar to the results for LLC-MK2 cells, 23SD treatment
Table 1
Hemagglutination of hRBC modiﬁed with different sialic acid linkages by hPIV1
and hPIV3.
Hemagglutination titers by:
hRBC hPIV1 hPIV3
Normal-hRBC 128 128
AUSD-hRBC o2 o2
23SD-hRBC o2 16
ST3-hRBC 256 256
ST6-hRBC o2 128
ST3N-hRBC 128 256
ST6N-hRBC o2 64
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decreased the infectivity of hPIV1 but not that of hPIV3 (Fig. 2C).
The results suggested that hPIV1 can use α2,3-linked sialic acids
and that hPIV3 can use α2,6-linked sialic acids in addition to α2,3-
linked sialic acids as virus receptors of host cell infection.
Infectivities of hPIV1 and hPIV3 in sialyltransferase-treated cells
To determine whether sialic acid linkages on the cell surface
regulate infectivity of hPIV1 and hPIV3, we investigated the
infectivities of hPIV1 and hPIV3 in sialyltransferase-treated Lec2
cells. Lec2 cells, surface sialic acid-deﬁcient mutant cells derived
from Chinese hamster ovary (CHO) Pro-5 cells, were sialylated
with ST3 or ST6. We measured viral infectivities in these sialylated
Lec2 cells. Both hPIV1 and hPIV3 infected ST3-treated cells but not
non-sialylated Lec2 cells (Fig. 3A). Unexpectedly, not only hPIV1
but also hPIV3 scarcely infected ST6-treated Lec2 cells, indicating
that hPIV3 cannot recognize the main α2,6-linked sialic acid
residues on the surface of Lec2 cells.
To conﬁrmwhether hPIV3 bound α2,6-linked sialic acids on the
Lec2 cell surface or not, we measured amounts of hPIV3 binding
on the sialylated Lec2 cell surface by ﬂowcytometric analysis. The
analysis revealed that hPIV3 could hardly bind to the surface of
ST6-treated Lec2 cells (Fig. 3B). Existence of α2,6-linked sialic acid
residues on the surface of ST6-treated Lec2 cells was conﬁrmed by
ﬂuorescent observation using SNA (Fig. 3C). In addition, inﬂuenza
A virus A/Memphis/1/1971 (H3N2) strain, which preferentially
binds to α2,6-linked sialic acids (Suzuki et al., 2000), infected
ST6-treated Lec2 cells but scarcely infected non-sialylated Lec2
cells (data not shown). In contrast to the results for hRBC, the
results suggested that hPIV3 could not bind to the main α2,6-
linked sialylated glycochains on Lec2 cells that SNA could recog-
nize and that hPIV binding speciﬁcity to sialic acid linkages
determines the viral infectivity.
Furthermore, we demonstrated infectivities of hPIV1 and hPIV3
in resialylated A549 cells. To prevent endogenous cellular resialyla-
tion, A549 cells were pretreated with 3Fax-Peracetyl Neu5Ac (ST-I),
a sialic acid analog and intracellular silalyltransferase inhibitor
Fig. 1. Hemadsorption activities of cell-expressed HN1 and HN3 glycoproteins by using hRBC modiﬁed with different sialic acid linkages. (A) Hemadsorption activities (%) of
HN1 and HN3 glycoproteins for sialidase-treated hRBC. HN1 or HN3 glycoproteins were expressed on the surfaces of COS-7 cells and the cells were incubated with the AUSD-
(not detected) or 23SD-treated hRBC (ﬁlled column) for 30 min on ice. hRBC that bound to the cell surfaces were quantiﬁed and calculated as a percentage relative to the
enzyme-untreated hRBC (B) Hemadsorption activities (%) of HN1 and HN3 glycoproteins for sialyltransferase-treated hRBC. The AUSD-treated hRBC were additionally
incubated with ST3 (gray column) or ST6 (hatched column) derived from Photobacterium for α2,3-linked or α2,6-linked speciﬁc resialylation. Hemadsorption activities were
calculated as described in (A). (C) Hemadsorption activities (%) of HN1 and HN3 glycoproteins for mammalian sialyltransferase-treated hRBC. The AUSD-treated hRBC were
incubated with ST3N (gray column) or ST6N (hatched column) derived from mammals. The hemadsorption activities were calculated as described in (A). The values are
means and standard deviations of triplicate experiments. N. D. means "not detected".
Fig. 2. Infectivities of hPIV1 and hPIV3 in sialidase-treated cells. (A) Infectivities (%) of hPIV1 and hPIV3 in 23SD-treated LLC-MK2 cells. Conﬂuent LLC-MK2 cells were treated
with serially diluted 23SD or AUSD for 2 h and were infected with hPIV1 (ﬁlled column) or hPIV3 (empty column). Virus-infected cells were detected by anti-virus antibodies,
and the infectivities were calculated as a percentage relative to the sialidase-untreated cells. (B) Flowcytometric analysis of the terminal sialic acid linkages on the surface of
sialidase-treated LLC-MK2 cells. Sialidase-treated LLC-MK2 cells were incubated with digoxigenin-conjugated MAA (ﬁlled column) or SNA (empty column) and then with the
FITC-conjugated anti-digoxin antibody. Lectin bindings were quantiﬁed as ﬂuorescence and calculated as a mean ﬂuorescence intensity (MFI) ratio relative to the sialidase-
untreated LLC-MK2 cells. (C) Infectivities (%) of hPIV1 and hPIV3 in 23SD-treated A549 cells. Conﬂuent A549 cells were treated with 23SD and were infected with hPIV1
(ﬁlled column) or hPIV3 (empty column). Infectivities were calculated as described in (A). The values are means and standard deviations of triplicate experiments. nnPo0.01
versus the results for hPIV1.
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(Rillahan et al., 2012), for 4 days. For ST-I-treated A549 cells, both
infectivities of hPIV1 and hPIV3 were decreased but still remained
(Supplementary Fig. 1). The decrease of hPIV3 infectivity was more
moderate than that of hPIV1, possibly because ST-I was a somewhat
weak inhibitor of endogenous cellular α2,6-sialylation (Rillahan et
al., 2012). ST-I-treated A549 cells were treated with AUSD for
complete desialylation and were then incubated with a reaction
solution containing CMP-Sia and ST3 or ST6 to resialylate α2,3-
linked or α2,6-linked sialic acids, respectively. We measured infec-
tivities of hPIV1 and hPIV3 in these resialylated A549 cells. ST3
treatment increased both infectivities of hPIV1 and hPIV3 compared
to incubation with CMP-Sia only (No ST) (Fig. 3D). In contrast to the
results for sialylated Lec2 cells, ST6 treatment increased the
infectivity of hPIV3 but not that of hPIV1 (Fig. 3D). hPIV3 recognized
α2,6-linked sialic acids on the A549 cell surfaces as viral receptors.
The results indicated that hPIV1 and hPIV3 can use various
terminal α2,3-linked sialic acids as viral receptors and that hPIV3
can also use terminal α2,6-linked sialic acid residues that exist in
speciﬁc glycochains on the surface of A549 cells but not on
Lec2 cells.
Sialic acid linkage recognition speciﬁcities of hPIV clinical isolates
To conﬁrm that clinical isolates of hPIV1 and hPIV3 show the
same silayl linkage recognition speciﬁcities as those of hPIV
laboratory strains, we examined the hemadsorption activity of
COS-7 cells infected with an hPIV1 clinical isolate hPIV1/Sendai-H/
1381/2007 (CL-1381) and an hPIV3 clinical isolate hPIV3/Sendai-
H/918/2009 (CL-918), which were isolated from infected patients
in 2007 and 2009, and we compared reduction of viral infectivity
by sialidase treatment (23SD and AUSD). COS-7 cells were infected
with CL-1381 or CL-918, and the sialic acid linkage recognition
speciﬁcities of the isolates were evaluated by hemadsorption
activities of HN glycoproteins expressed on the virus-infected cell
surfaces. CL-1381-infected cells bound to ST3-treated hRBC. In
contrast, CL-918-infected cells adsorbed both ST3- and ST6-treated
hRBC (Fig. 4A). The cell infected with the clinical strains hardly
bound to AUSD-hRBC. We also measured the infectivities of CL-
1381 and CL-918 in 23SD-treated LLC-MK2 cells and conﬁrmed
that CL-918 infection shows more resistance to 23SD treatment
than does CL-1381 infection (Fig. 4B). The hPIV clinical isolates
showed sialic acid linkage recognition speciﬁcities similar to those
of hPIV laboratory strains.
Discussion and conclusion
In the present study, we conﬁrmed binding speciﬁcities of
hPIV1 and hPIV3 for sialic acid linkages at all glycoconjugates on
the surface of hRBC, LLC-MK2 cells, A549 cells and Chinese hamster
ovary cell mutants (Lec2 cells and Pro-5 cells). The cell surfaces
were treated with several sialidases and sialyltransferases. A
Fig. 3. Infectivities of hPIV1 and hPIV3 in sialyltransferase-treated Lec2 cells and A549 cells. (A) Infectivities (%) of hPIV1 and hPIV3 in sialyltransferase-treated Lec2 cells.
Lec2 cell monolayers were incubated with a reaction solution containing CMP-Sia and ST3 or ST6 (ST3, gray column; ST6, hatched column). As a control, a Lec2 cell
monolayer was incubated with CMP-Sia only (No ST, ﬁlled column). The sialylated cells were infected with hPIV1 or hPIV3 and their infectivities were calculated as a
percentage relative to parental Pro-5 cell monolayers. The values are means and standard deviations of triplicate experiments. N.D. means “not detected”. (B) hPIV3 binding
activities to sialylated Lec2 cells. The ST3-treated (ST3, solid line), ST6-treated (ST6, dotted line), or enzyme-untreated Lec2 cells (No ST, gray shading) were incubated with
hPIV3 for 1 h on ice. The cells were incubated with anti-virus antibodies on ice for 30 min and then incubated with PE-conjugated anti-rabbit IgG on ice for 30 min. The
ﬂuorescence intensities of the cells were analyzed using a ﬂowcytometer. (C) Lectin staining of sialyltransferase-treated Lec2 cells. The ST3- or ST6-treated Lec2 cells were
stained with FITC-conjugated SNA (green) or biotin-conjugated MAL-II, followed by FITC-conjugated streptavidin (green). Nuclei were stained with DAPI (blue). Scale
bar¼40 μm. (D) Infectivities (%) of hPIV1 and hPIV3 in sialyltransferase-treated A549 cells. A549 cell monolayers were pretreated with ST-I for 4 days and were treated with
AUSD for 3 h. The desialylated cells were incubated with a reaction solution containing CMP-Sia and ST3 or ST6 for 2 h to resialylate α2,3-linked or α2,6-linked sialic acids
(ST3, gray column; ST6, hatched column). As a control, the cells were incubated with CMP-Sia only (No ST, ﬁlled column). The resialylated cells were infected with hPIV1 or
hPIV3 and their infectivities were calculated as a percentage relative to ST-I-treated and AUSD-untreated monolayers. The values are means and standard deviations of
triplicate experiments. nPo0.05, nnPo0.01 versus the results for each no ST.
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hemagglutination assay of the virus particles and a hemadsorption
assay of HN glycoproteins-expressing COS-7 cells revealed that
both hPIV1 and hPIV3 are bound to α2,3-linked sialic acid residues
on the surface of hRBC and that hPIV3 is additionally bound to
α2,6-linked sialic acid residues. Viral infectivity assays using the
sialidase-treated A549 cells, sialidase-treated LLC-MK2 cells and
sialyltransferase-treated A549 cells showed that the different
binding speciﬁcities of hPIV1 and hPIV3 for sialic acid linkages is
a critical factor for viral infectivity. In addition, the hPIV clinical
isolates showed sialic acid linkage recognition speciﬁcities similar
to those of hPIV laboratory strains in a hemadsorption assay for
ST3- or ST6-treated hRBC and infectivity assay for 23SD-treated
LLC-MK2 cells. Taken together, we concluded that both hPIV1 and
hPIV3 mainly recognize terminal α2,3-linked sialic acid residues as
virus receptors and that hPIV3 also recognizes terminal α2,6-linked
sialic acid residues.
Some previous reports have indicated that hPIVs recognize not
only terminal sialic acids but also internal glycochain structures,
especially the polylactosamine motif. hPIV1 and hPIV3 preferen-
tially bind to sialic acids at the terminals of branching polylacto-
samine structures (Suzuki et al., 2001b). In the primary human
airway epithelium, hPIV3 exclusively infects ciliated epithelial cells
(Zhang et al., 2005), which have lactosamine motifs that are
recognized by erythrina crista lectin or oligosaccharide sequence-
speciﬁc antibodies (Loveless and Feizi, 1989; Vierbuchen et al.,
1988). Different from other respiratory paramyxoviruses, such as
Sendai virus, that mainly recognize terminal sialic acids (Markwell
and Paulson, 1980; Markwell et al., 1981; Suzuki et al., 2001b,
1985), the internal polylactosamine motifs as well as terminal
sialic acids may be important factors for cell surface binding and
infection of hPIV1 and hPIV3. In studies on glycochain recognition
of hPIV1 and hPIV3 by a glycoarray, it was shown that hPIV3 has
no binding to glycochains containing α2,6-linked sialic acid
(Amonsen et al., 2007; Song et al., 2011). However, the glycoarray
probably contains a few kinds of internal glycochain structures in
length and branching, compared with natural glycochains on cell
surfaces. hPIV3 recognized α2,6-linked sialic acids on human A549
cells and hRBC but not those on Lec2 cells derived from the CHO
cell line. hPIV3 may need a speciﬁc internal glycochain when it
binds to terminal α2,6-linked sialic acids, for example, human
blood group I antigens that contain internal branching polylacto-
samine motifs and exist on the surfaces of hRBC, A549 cells and
ciliated human bronchial epithelial cells but not on CHO cells
(Inaba et al., 2003; Loveless and Feizi, 1989), and hPIV1 and hPIV3
strongly bind (Suzuki et al., 2001b).
In the clinical site, hPIV3 causes more severe bronchiolitis and
lower pneumonia. On the other hand, hPIV1 causes only mild
infection that is limited to the upper respiratory tract (Chanock,
2001). Human trachea cells predominantly express α2,6-linked
sialic acids (Baum and Paulson, 1990). The difference between
hPIV1 and hPIV3 in tropism and pathogenesis in vivo may result
from the ability of hPIV3 to recognize α2,6-linked sialic acid.
Further characterization of sialic acid linkages and the internal
glycochain structure motif distributions in the human respiratory
tract would reveal the biological signiﬁcance of tropism and
pathogenesis of hPIV1 and hPIV3.
Materials and Methods
Cells, viruses and antibodies
LLC-MK2 cells were maintained in Eagle's minimum essential
medium (MEM) supplemented with 5% heat-inactivated fetal
bovine serum (FBS). COS-7 cells and A549 cells were maintained
in Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented
with 10% FBS. Lec2 cells and Pro-5 cells, derivatives of a CHO cell
line, were maintained in alpha minimal essential medium supple-
mented with 10% FBS and 40 μg/ml of L-proline (Sigma-Aldrich, St.
Louis, MO). The hPIV1 C35 strain and the hPIV3 C243 strain were
kindly provided by Allen Portner (St. Jude Children's Research
Hospital). These hPIVs were propagated in LLC-MK2 cells. An hPIV1
clinical isolate CL-1381 and an hPIV3 clinical isolate CL-918 were
provided by the Virus Research Center, Clinical Research Division,
Sendai Medical Center, Sendai, Japan. CL-1381 and CL-918 were
isolated from infected patients in 2007 and 2009, respectively, and
were passaged two times in human melanoma HMV-II cells and
then four times in LLC-MK2 cells. Rabbit anti-hPIV1 antibody and
rabbit anti-hPIV3 antibody were prepared by immunization with
each hPIV as described previously (Suzuki et al., 2001a) and
Fig. 4. Sialic acid linkage recognition speciﬁcities of hPIV clinical isolates. (A) Hemadsorption activities (%) of hPIV1 clinical isolate (CL-1381)-infected cells and hPIV3 clinical
isolate (CL-918)-infected cells for sialyltransferase-treated hRBC. COS-7 cells were infected with CL-1381 or CL-918 and incubated for 2 days. The cells were incubated with
AUSD- (empty column), ST3- (gray column), or ST6-treated hRBC (hatched column) for 30 min on ice. hRBC that bound to the cell surfaces were quantiﬁed and calculated as a
percentage relative to enzyme-untreated hRBC. Non-infected cells were used as a negative control. (B) Infectivities (%) of CL-1381 and CL-918 in 23SD- or AUSD-treated LLC-
MK2 cells. Conﬂuent LLC-MK2 cells were treated with 23SD or AUSD for 2 h and infected with CL-1381 (ﬁlled column) or CL-918 (empty column). Virus-infected cells were
detected by anti-virus antibodies. The infectivities were calculated as a percentage relative to those of sialidase-untreated cells. The values are means and standard deviations
of triplicate experiments. nPo0.05, nnPo0.01 versus the results for each CL-1381. N. D. means "not detected".
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puriﬁed on a Protein G HiTrapTM Protein G HP (CE Healthcare
Biosciences Corp., Priscataway, NJ).
Preparation of sialic acid linkage-modiﬁed red blood cells
hRBC were collected from a healthy adult and washed 3 times
with phosphate-buffered saline (PBS; pH 7.2, 131 mM NaCl, 14 mM
Na2HPO4 and 2.7 mM KCl) (Normal-hRBC). For complete desialyla-
tion, 10% of Normal-hRBC were incubated with PBS containing
25 mU/ml of AUSD (Nacalai Tesque, Kyoto, Japan) at 37 1C for 2 h
and washed with PBS 5 times (AUSD-hRBC). For desialylation of
α2,3-linked sialic acids, 10% of Normal-hRBC were incubated with
PBS containing 100 U/ml of 23SD (New England Biolabs Inc.,
Ipswich, MA) and 5 mM CaCl2 at 37 1C for 1 h and washed with
PBS 5 times (23SD-hRBC). For resialylation of α2,3-linked sialic
acids, 10% of AUSD-hRBC were incubated with PBS containing 1%
albumin from bovine serum (BSA; Sigma-Aldrich, St. Louis, MO),
1.5 mg/ml of CMP-Sia (Nacalai Tesque, Kyoto, Japan) and 20 mU/ml
of ST3N, which was prepared from BmNPV bacmid-injected silk-
worm larvae as described previously (Ogata et al., 2009), at 37 1C
for 16 h and washed with PBS 5 times (ST3N-hRBC) or were
incubated with PBS containing 1.5 mg/ml of CMP-Sia and
100 mU/ml of ST3 (Cosmo Bio Co., Ltd., Tokyo, Japan) at 37 1C for
17 h and washed with PBS 5 times (ST3-hRBC). For resialylation of
α2,6-linked sialic acids, 10% of AUSD-hRBC were incubated with
PBS containing 1% BSA, 1.5 mg/ml of CMP-Sia and 20 mU/ml of
ST6N (Calbiochem, San Diego, CA) at 37 1C for 16 h and washed
with PBS 5 times (ST6N-hRBC) or were incubated with PBS con-
taining 1.5 mg/ml of CMP-Sia and 75 mU/ml of ST6 (Cosmo Bio Co.,
Ltd., Tokyo, Japan) at 37 1C for 17 h and washed with PBS 5 times
(ST6-hRBC).
Hemagglutination assays
Each virus was serially diluted with 50 μl of PBS on a microtiter
plate. Fifty microliters of 0.8% (vol/vol) of each type of hRBC
(Normal-hRBC, AUSD-hRBC, 23SD-hRBC, ST3N-hRBC, ST3-hRBC,
ST6N-hRBC and ST6-hRBC) in PBS was added to each well. The
hemagglutination unit (HAU) was deﬁned as the maximum dilu-
tion of virus that showed hemagglutination after 2 h. The plates
were kept on ice during the assays to prevent the viral sialidase
and fusion activities
Plasmid construction of HN genes
HN genes were subcloned into the pCAGGS/MCS expression
vector as described previously (Takaguchi et al., 2011). Brieﬂy, each
viral RNA was isolated from virus particles with TRIzol reagent
(Invitrogen Corp., Carlsbad, CA) according to the manufacturer's
instructions. Full-length cDNAs of the HN gene from hPIV1 (HN1
gene) and the HN gene from hPIV3 (HN3 gene) were ampliﬁed by
using a TaKaRa RNA PCR™ kit Ver. 3.0 (TaKaRa Bio Inc., Shiga,
Japan). The HN1 and HN3 genes were subcloned into the site
between EcoR I and Xho I of the pCAGGS/MCS vector (pCAGGS-
HN1 and pCAGGS-HN3, respectively).
Hemadsorption assays
To determine the hemadsorption activity of HN glycoproteins, a
conﬂuent monolayer of COS-7 cells in a 48-well plate was
transfected with 300 ng of pCAGGS-HN1 or pCAGGS-HN3 using
the transfection reagent TransIT-LT1 (Mirus, Madison, WI) accord-
ing to the manufacturer's instructions. The cells were mock-
treated without plasmids as a control. After incubation at 37 1C
for 6 h, the transfected cells were washed with PBS and then
cultured in 300 μl of a serum-free medium (Hybridoma-SFM; SFM,
Invitrogen, Corp., Carlsbad, CA). After incubation at 37 1C for 48 h,
the cells were washed with PBS and incubated with 0.5% of each
sialic acid linkage-modiﬁed hRBC in SFM for 30 min on ice. The
cells were washed 3 times with SFM and incubated with 100 μl of
ultrapure water for 10 min on ice. Fifty microliters of the super-
natant was applied to a 96-well plate, and the amount of
hemoglobin was determined by measuring the absorbance at
415 nm with a reference wavelength of 630 nm (Takaguchi et al.,
2011). The amount of hemoglobin in non-transfected cells was
tested as a negative control.
To determine the hemadsorption activity of hPIV clinical
isolate-infected cells, a conﬂuent monolayer of COS-7 cells in the
48-well plate was infected with CL-1381 or CL-918 diluted by SFM
at a multiplicity of infection (MOI) of 1 for 30 min at room
temperature. The wells were washed with PBS and then the cells
were cultured in 300 μl of SFM. After incubation at 37 1C for
2 days, the cells were washed with SFM and incubated with 0.5%
each sialic acid linkage-modiﬁed hRBC in SFM for 30 min on ice.
The amount of hemoglobin was determined as described above.
Non-infected cells were tested as a negative control.
Virus infectivity assay for sialidase-treated cells
Conﬂuent monolayers of LLC-MK2 cells in a 12-well plate were
washed with PBS and treated with pH 5.5 SFM containing 40 mU/
ml of AUSD or 0, 40, 80 and 100 mU/ml of 23SD (TaKaRa Bio Inc.,
Shiga, Japan) at 37 1C for 2 h. The wells were washed with PBS and
infected with each virus diluted by SFM at an MOI of 0.01 for 1 h
on ice. The wells were washed with PBS and then the cells were
cultured in 1 ml of MEM containing 5% FBS. The plate was
incubated at 37 1C for 12 h. The monolayers were ﬁxed with 1 ml
of cold methanol for 5 min. Virus-infected cells were detected by
probing with a rabbit anti-hPIV1 antibody or rabbit anti-hPIV3
antibody at room temperature for 30 min, followed by horseradish
peroxidase (HRP)-conjugated Protein A (Sigma-Aldrich, St. Louis,
MO) at room temperature for 30 min as described previously
(Takahashi et al., 2012). Each step was preceded by washing the
wells three times with PBS. Finally, the virus-infected cells were
stained by addition of an immunostaining reagent containing
H2O2, N,N-diethyl-p-phenylenediamine sulfate and 4-chloro-1-
naphthol in 100 mM citrate buffer (pH 6.0) as described previously
(Conyers and Kidwell, 1991; Takahashi et al., 2008). Infectivity (%)
was calculated as a percentage of the number of stained cells
relative to the sum total of that in the sialidase-untreated well
under 3 optical observations at a magniﬁcation of 100.
For the A549 cell line, conﬂuent monolayers in a 24-well plate
were washed with PBS and treated with pH 5.5 SFM containing
50 U/ml of 23SD (New England BioLabs, Ipswich, MA) at 37 1C for
2 h. The wells were washed with PBS and infected with each virus
diluted by SFM at an MOI of 0.01 for 30 min at room temperature.
The wells were washed with PBS and then the cells were cultured
in 500 μl of SFM. The plate was incubated at 37 1C for 14 h. The
monolayers were ﬁxed with 500 μl of cold methanol for 5 min.
Virus-infected cells were detected by anti-hPIV antibodies and
infectivity (%) was calculated as a percentage relative to the
sialidase-untreated cells as described above.
To determine virus infectivity of hPIV clinical isolates, conﬂuent
monolayers of LLC-MK2 cells in the 48-well plate were washed
with PBS and treated with pH 5.5 SFM containing 50 U/ml of 23SD
(New England BioLabs, Ipswich, MA) or 40 mU/ml of AUSD at 37 1C
for 2 h. The wells were washed with PBS and infected with hPIV1
and hPIV3 clinical isolates, CL-1381 or CL-918, diluted by SFM at an
MOI of 0.01 for 30 min at room temperature. The wells were
washed with PBS and then the cells were cultured in 300 μl of
SFM. The plate was incubated at 37 1C for 14 h. The monolayers
were ﬁxed with 300 μl of cold methanol for 5 min. Virus-infected
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cells were detected by anti-hPIV antibodies. Infectivity (%) was
calculated as a percentage relative to the sialidase-untreated cells
as described above.
Lectin binding assay
A conﬂuent monolayer of LLC-MK2 cells in the 12-well plate
was harvested by treatment with 0.125% trypsin and ﬁxed with
4% paraformaldehyde for 15 min at room temperature. The cells
were washed with PBS 3 times and treated with 100 mU/ml
of 23SD (TaKaRa Bio Inc., Shiga, Japan) or 40 mU/ml of AUSD at
37 1C for 12 h. They were washed with PBS 3 times, incubated in
PBS containing 20 μg/ml of digoxigenin-conjugated SNA (Roche
Applied Science, Mannheim, Germany) or 10 μg/ml of digoxigenin-
conjugated MAA (Roche Applied Science, Mannheim, Germany) for
1 h at 4 1C, and then incubated with 50 μg/ml of ﬂuorescein
isothiocyanate (FITC)-conjugated mouse anti-digoxin monoclonal
antibody (Sigma-Aldrich, St Louis, MO) for 1 h at 4 1C. Fluorescence
for cells was measured with an excitation of the 488-nm line of an
argon laser on a FACSCanto II ﬂow cytometer (BD, Franklin Lakes,
NJ). At least 1104 cells were analyzed for each sample.
Virus infectivity assay for sialyltransferase-treated cells
To determine virus infectivity in resialylated Lec2 cells, 70%
conﬂuent monolayers of Lec2 cells in the 96-well plate were
incubated with SFM containing 1.5 mM of CMP-Sia and 100 mU/
ml of ST3 or 200 mU/ml of ST6 at 37 1C for 12 h. The cells were
washed with PBS and infected with each virus diluted by SFM at
an MOI of 0.1 for 30 min at room temperature. The wells were
washed with PBS and then with the cells were cultured in 50 μl of
SFM. The plate was incubated overnight at 37 1C. The monolayers
were ﬁxed with 100 μl of cold methanol and virus-infected cells
were detected by anti-hPIV antibodies as described above. Infec-
tivity (%) was calculated as a percentage relative to the parental
cell line Pro-5 cells of the Lec2 cells under 3 optical observations.
To determine virus infectivity in resialylated A549 cells after
desialylation, 70% conﬂuent monolayers of A549 cells in the
24-well plate were pretreated with 200 μM of a sialyltransferase
inhibitor, ST-I (Millipore, Billerica, MA), for 4 days to deactivate
cellular sialyltransferase activity. The cells were washed with PBS
and incubated with 100 mU/ml of AUSD at 37 1C for 3 h. Then the
cells were washed with PBS and incubated with SFM containing
1.0 mM of CMP-Sia and 100 mU/ml of ST3 or 150 mU/ml of ST6 at
30 1C for 2 h. The cells were washed with PBS and infected with
each virus diluted by SFM at an MOI of 0.01 for 30 min. The wells
were washed with PBS and then the cells were cultured in 500 μl
of SFM. The plate was incubated overnight at 37 1C. The mono-
layers were ﬁxed with 500 μl of cold methanol and virus-infected
cells were detected by anti-hPIV antibodies as described above.
Infectivity (%) was calculated as a percentage relative to the ST-I-
treated and sialyltransferase-untreated cells under 3 optical
observations.
Virus binding assay
Seventy percent conﬂuent monolayers of Lec2 cells in the
24-well plate were resialylated with ST3 or ST6 as described above
and harvested by treatment with 0.125% trypsin. The cells were
incubated in PBS containing 27 HAU of hPIV3 for 1 h on ice and
ﬁxed with 4% paraformaldehyde for 30 min. The cells were
incubated in PBS containing rabbit anti-hPIV3 antibody for
30 min on ice and then with phycoerythrin (PE)-conjugated goat
anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) for
30 min on ice. Fluorescence for cells was measured with an
excitation of 488-nm line of an argon laser on a FACSCanto II ﬂow
cytometer. At least 1104 cells were analyzed for each sample.
Lectin staining
Seventy percent conﬂuent monolayers of Lec2 cells in the
96-well plate were resialylated with ST3 or ST6 as described
above. The cells were ﬁxed with 2% paraformaldehyde for
20 min at room temperature and were washed with PBS 3 times.
To determine α2,3-linked sialic acids, the cells were incubated
with PBS containing 100 μg/ml of biotin-conjugated Maackia
amurensis lection II (MAL-II, Vector Laboratories, Inc., Burlingame,
CA) at room temperature for 30 min, followed by 20 μg/ml of FITC-
conjugated streptavidin (Vector Laboratories, Inc., Burlingame, CA)
at room temperature for 30 min. To determine α2,6-linked sialic
acids, the cells were incubated with PBS containing 20 μg/ml of
FITC-conjugated SNA (Vector Laboratories, Inc., Burlingame, CA) at
room temperature for 30 min. Nuclei were stained with 2 μg/ml of
4, 6-diamidino-2-phenylindole dihydrochloride (DAPI; Dojindo
Laboratories, Kumamoto, Japan) at room temperature for 30 min.
Lectin binding and nuclei staining were observed by using a
ﬂuorescent microscope (OLYMPUS IX71, Olympus, Tokyo, Japan).
Statistical analysis
Results are shown as averages. Student's t-test was used to
perform statistical analyses.
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